Mental Health Parity Act (MHPAEA) Explained" class="auto-link">mhpaea">Insurance Denied Addiction Treatment? How to Appeal SUD and Residential Rehab Denials Under MHPAEA

Addiction — or Substance Use Disorder (SUD) — is a chronic, relapsing brain disease affecting more than 48 million Americans. Treatment requires a continuum of care: medical detoxification, residential rehabilitation, partial hospitalization, intensive outpatient, and ongoing outpatient therapy. Insurance companies routinely deny these services, often at the very moment patients and families are fighting for their lives.

These denials are often illegal under the Mental Health Parity and Addiction Equity Act (MHPAEA) — and they are among the most frequently overturned categories in External Independent Review: Complete Guide" class="auto-link">external review.

Why Insurers Deny Addiction Treatment

Residential rehab denied as "not medically necessary." The most common denial: the insurer claims the patient doesn't meet their internal criteria for residential treatment — often because the patient isn't currently experiencing an acute medical crisis. This ignores that residential care's purpose is to prevent acute crisis, not to manage one.

Step-down required before fully completing treatment. Insurers may push patients from residential to partial hospitalization or intensive outpatient before clinical stabilization, leading to relapse and return to higher levels of care — which costs more in the long run.

Detox approved but rehabilitation denied. Insurers may cover medical detoxification but then deny the rehabilitation phase that is clinically necessary to prevent immediate relapse.

Concurrent review denials. Insurers conduct daily or weekly reviews during residential stays and deny continued coverage when their reviewer (often a nurse or physician who has never examined the patient) disagrees with the treatment team.

Out-of-network facility. Specialized SUD treatment programs — particularly dual-diagnosis programs, gender-specific programs, or programs addressing co-occurring trauma — are rarely in-network in every region.

Medication-assisted treatment (MAT) denied. Buprenorphine (Suboxone, Subutex), naltrexone (Vivitrol, ReVia), and methadone for opioid use disorder face Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization barriers that delay life-saving treatment.

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered charge), B15 (authorization not obtained), CO-4 (service inconsistency), CO-125 (benefit maximum reached).

MHPAEA: Your Most Powerful Legal Tool

The Mental Health Parity and Addiction Equity Act (MHPAEA), enacted in 2008 and strengthened in 2024, requires that treatment limitations on mental health and substance use disorder benefits not be more restrictive than comparable limitations on medical/surgical benefits.

This means: if your insurer covers 30-day inpatient rehabilitation for cardiac surgery without case-by-case daily review, it cannot conduct daily concurrent review of a 30-day residential SUD program. If the insurer covers unlimited outpatient physical therapy visits, it cannot cap outpatient SUD counseling visits.

The 2024 MHPAEA final rule (effective in 2025) significantly strengthened enforcement by:

• Requiring insurers to perform and disclose nonquantitative treatment limitation (NQTL) comparative analyses
• Giving regulators authority to require plan corrections when disparities are found
• Extending parity protections to Medicaid managed care plans

How to invoke MHPAEA in your appeal:

1. Write formally to the insurer requesting the NQTL comparative analysis showing how their SUD treatment criteria compare to criteria for analogous medical/surgical benefits
2. Identify specific disparities: daily concurrent review for SUD not applied to medical rehab; lower reimbursement rates for behavioral health providers; geographic access limitations not applied to medical care
3. File a complaint with the Department of Labor (for employer-sponsored plans), the Department of Health and Human Services (for Marketplace plans), or your state insurance commissioner (for state-regulated plans)

ASAM Criteria: The Clinical Standard for Level of Care

The American Society of Addiction Medicine (ASAM) Criteria (3rd edition, updated 2023) is the most widely accepted clinical framework for determining appropriate level of care in SUD treatment. ASAM criteria evaluate patients across six dimensions:

1. Acute intoxication and/or withdrawal potential
2. Biomedical conditions and complications
3. Emotional, behavioral, or cognitive conditions and complications
4. Readiness to change
5. Relapse, continued use, or continued problem potential
6. Recovery and living environment

When an insurer denies residential treatment or requires a step-down, your appeal should cite ASAM criteria explicitly — showing how the patient's assessment across these six dimensions supports the level of care being requested. A treating addiction specialist or SUD counselor should complete this assessment in writing.

The Wit v. United Behavioral Health Precedent

The landmark 2019 Wit v. United Behavioral Health ruling (Northern District of California) found that UBH used internally developed guidelines for SUD and mental health treatment that were more restrictive than generally accepted medical standards — including ASAM criteria. The court found these guidelines improperly focused on acute symptom management rather than underlying chronic disease, in violation of MHPAEA.

While the case has had a complex appellate history, the ruling established an important principle: insurers cannot use internal criteria that are more restrictive than recognized clinical guidelines. If your insurer (particularly UnitedHealthcare/UBH) denies SUD treatment using criteria that diverge from ASAM, the Wit ruling is directly applicable.

Medication-Assisted Treatment Appeals

For MAT denials (buprenorphine, naltrexone, methadone):

• Cite the Surgeon General's 2016 report on addiction, which endorses MAT as evidence-based treatment
• Reference SAMHSA (Substance Abuse and Mental Health Services Administration) clinical guidelines on opioid use disorder treatment
• Note that buprenorphine and naltrexone are FDA-approved for opioid use disorder
• Apply parity principles: if a diabetic patient can get insulin without prior authorization, an opioid use disorder patient should be able to get buprenorphine without prior authorization

Step-by-Step Appeal Strategy

Step 1: Request all denial documentation. Get the full denial letter, the clinical criteria used, and the credentials of the reviewing clinician. In many states, you have a right to a clinical reviewer at the same level as the treating clinician (addiction specialist reviewing addiction specialist's decision).

Step 2: Submit a complete ASAM criteria assessment. The treating addiction specialist or licensed clinical social worker should complete a written ASAM dimensional assessment justifying the requested level of care.

Step 3: Invoke MHPAEA. Request the NQTL comparative analysis in writing. Identify the comparable medical/surgical benefit being used for comparison and document any disparities.

Step 4: Request an urgent or expedited review. Untreated SUD — particularly opioid use disorder — presents imminent risk of overdose death. Most states allow expedited appeals for urgent medical situations. Frame the denial as an urgent health risk.

Step 5: File a state complaint in parallel. File a complaint with your state insurance commissioner simultaneously with your internal appeal. Regulatory pressure often accelerates resolution.

Supporting Evidence to Gather

• ASAM criteria dimensional assessment from treating clinician
• Addiction medicine or psychiatry evaluation
• Prior treatment history and outcomes
• Medical records documenting withdrawal risk, comorbidities
• MHPAEA NQTL comparative analysis request (in writing)
• SAMHSA clinical guidelines on OUD treatment
• Wit v. UBH case summary (for UBH-related denials)
• State insurance commissioner complaint form

Fight Back With ClaimBack

Addiction treatment denials can cost lives. ClaimBack helps you build a rapid, legally grounded appeal that addresses every ground the insurer cited — giving patients and families the best chance of getting treatment approved.

Start your addiction treatment appeal today

Related Reading

• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?
• Insurance Ombudsman Guide: How to File a Complaint